多西他赛每周给药联合顺铂治疗晚期非小细胞肺癌  

Docetaxel Administered Weekly Infusion Plus Cisplatin For Advanced non-small-cell Lung Caner

作　　者：张翠英[1] 李文新[1] 贾明[1] 

机构地区：[1]内蒙古自治区医院肿瘤科,内蒙古呼和浩特010017

出　　处：《内蒙古医学杂志》2007年第3期313-314,共2页Inner Mongolia Medical Journal

摘　　要：目的:研究多西他赛(泰索帝)每周给药联合顺铂治疗晚期非小细胞肺癌的疗效和不良反应。方法:多西他赛35mg/m2,每周给药,连用3周休息1周;顺铂75mg/m2,每周期的第1d给药,每28d为1个治疗周期。3周期评价疗效。结果:有16例患者部分缓解,占全部入组病例(45例)的36%,中位生存时间11.3个月(范围5-28个月);1年生存率51%;Ⅲ-Ⅳ度的粒细胞减少为27%,非血液系统毒副反应为乏力、恶心及液体潴留。结论:多西他赛每周给药联合顺铂治疗初治的晚期非小细胞肺癌疗效较好,骨髓毒性较轻。Objective：To study the efficacy and safety of docetaxel administrated weekly plus cisplatin in the treatment for patients with advanced non - small - cell lung cancer （NSCLC）. Methods： Fourty - five patients with stage ⅢB stage Ⅳ not treated previously by chemotherapy, or recurrent after operation NSCLC received intravenous infusions of docetaxel at 35mg/m^2 three consecutive weeks, followed by a week of rest：and intravenous infusions of cisplatin at 75mg/m^2 every four weeks, that of one period. The efficacy were evaluated aftor Hree Periods. Results： there were 16 partial responses for an objective response rate of 36 %. The median survival was 11.3 months（range 5 - 28months）, and the 1 - year survival rate was 51%. Hematologic toxicities, which were mild, included grade Ⅲ/Ⅳ neutropenia in 27 %. The common nonhematologic toxicities included nausea and Asthenia. Conclusions： Consecutive weekly administrations of docetaxel for 3 weeks plus cisplatin produce minimal myelosuppression and shows activity in the treatment of patients without previous chemotherapy with advanced NSCLC.

关 键 词：肺肿瘤 晚期非小细胞肺癌 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤]